Market News

Prophylactic Human Vaccine Market Global Growth by Manufacturers, Regions, Product Types, Major Application Analysis

Prophylactic Human Vaccine Market
Prophylactic Human Vaccine Market

Prophylactic human vaccines stimulate the immune response and are intended for ameliorating the effects of future infection caused by pathogens in human beings. Novel vaccine development technologies such as viral-like particles are used in developing Hepatitis B Virus (HBV) vaccines, and Human Papilloma Virus (HPV) vaccines. For instance, in March 2014, CureVac AG received EUR 2 million Vaccine Prize from European Commission for its novel RNActive vaccine technology. This RNActive vaccine technology enables production of safe, efficacious, and cost-effective vaccines that are protected against elevated temperature as well as inadvertent freezing.

Download PDF Brochure Of This Research Report @

Prophylactic Human Vaccine Market – Drivers

Increasing number of pipeline studies and rising involvement of key players for vaccine development is expected to propel growth of the prophylactic human vaccine market during the forecast period. For instance, in October 2018, CureVac AG, announced to initiate dose escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a prophylactic vaccine encoding RABV-G, the rabies virus glycoprotein. This will enable vaccinated individual’s own cells to produce RABV-G protein, by which immune response gets triggered. This study is estimated to complete in January 2021.

Prophylactic Human Vaccine Market – Regional Analysis

On the basis of region, the global prophylactic human vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Geographically, North America is probable to lead in the global prophylactic human vaccine market, owing to receiving large number of research grants by government. For instance, in September 2018, GeoVax Labs, Inc., U.S.-based company recieved grant of US$ 2,442,307 by the U.S. Army Medical Research Acquisition Activity. The grant was awarded as a cooperative agreement for novel Lassa Fever (LF) vaccine (GEO-LM01) development program. GEO-LM01 uses Modified Vaccinia Ankara (MVA) and Virus-Like Particle (VLP) vaccine platform that has been demonstrated to be safe and induce antibody responses in patients. Moreover, MVA-VLP platform has shown effective results in other cases such as GeoVax’s prophylactic HIV vaccine, GeoVax’s Ebola (EBOV) vaccine, and GeoVax’s Zika vaccine in its respective preclinical studies.

The key players operating in prophylactic human vaccine market include, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc., Altimmune, Inc., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Shanghai BravoBio Co., Ltd., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited, BiondVax Pharmaceuticals Ltd., and SK Chemicals Co., Ltd.

TechnoBleak Media Inc. ( is an Independent Online News Portal intended to deliver news related to Apps, Technology, Startups, and Gadgets. It is run by writers and co-workers living in different parts of the world. We aim to create high-quality content for our readers who like to read business and technology news & updates. At TechnoBleak, we offer the latest news, breakthroughs, and analysis with emphasis on expert opinion and commentary from the Technology and Startups community.

Office Address:

TechBleak Media Inc.
501 Boylston Street,
Boston, MA 02116.

EMail: [email protected]